Q4 EPS Estimate for Dynavax Technologies Boosted by Analyst

Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) - Equities researchers at William Blair increased their Q4 2024 EPS estimates for shares of Dynavax Technologies in a research report issued on Monday, January 13th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings of $0.02 per share for the quarter, up from their previous forecast of $0.01. The consensus estimate for Dynavax Technologies' current full-year earnings is $0.19 per share. William Blair also issued estimates for Dynavax Technologies' FY2026 earnings at $0.48 EPS.

A number of other equities research analysts have also commented on the company. StockNews.com raised Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Tuesday. HC Wainwright raised their target price on shares of Dynavax Technologies from $29.00 to $31.00 and gave the stock a "buy" rating in a report on Tuesday.

Dynavax Technologies Trading Down 0.7 %

DVAX stock traded down $0.09 during midday trading on Thursday, hitting $12.39. 1,290,391 shares of the company's stock were exchanged, compared to its average volume of 1,979,409. Dynavax Technologies has a one year low of $9.74 and a one year high of $14.30. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The company has a market cap of $1.63 billion, a PE ratio of 95.32 and a beta of 1.34. The stock's fifty day moving average price is $12.78 and its 200-day moving average price is $11.66.

Institutional Trading of Dynavax Technologies

A number of institutional investors have recently modified their holdings of the company. GAMMA Investing LLC grew its holdings in shares of Dynavax Technologies by 55.1% during the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock worth $52,000 after buying an additional 1,457 shares in the last quarter. Sanctuary Advisors LLC boosted its position in Dynavax Technologies by 9.1% during the 3rd quarter. Sanctuary Advisors LLC now owns 17,727 shares of the biopharmaceutical company's stock worth $197,000 after acquiring an additional 1,484 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Dynavax Technologies by 44.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 1,679 shares in the last quarter. US Bancorp DE raised its holdings in shares of Dynavax Technologies by 291.4% in the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 2,034 shares during the last quarter. Finally, Parkman Healthcare Partners LLC raised its holdings in shares of Dynavax Technologies by 1.2% in the third quarter. Parkman Healthcare Partners LLC now owns 219,451 shares of the biopharmaceutical company's stock valued at $2,445,000 after purchasing an additional 2,629 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.